Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01864460 · ClinicalTrials.gov registry record · NA

Improving Autonomic Function and Balance in Diabetic Neuropathy

A NA study of Diabetes and Neuropathy, sponsored by VA Office of Research and Development.

Active
Registry status
NA
Development phase
60
Enrollment target
1
Study location

NCT01864460 is a NA study of Diabetes and Neuropathy that is active but no longer recruiting, run by VA Office of Research and Development. The registered enrollment target is 60 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01864460, a NA study of Diabetes and Neuropathy, is active but no longer recruiting, sponsored by VA Office of Research and Development.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

Type 2 diabetes (DM2) affects nearly 20 million people in the United States while impaired glucose regulation (IGR), which includes impaired glucose tolerance (IGT), impaired fasting glucose (IFG), and early diabetes affects a considerably larger but unknown population group. At the current time there is no effective therapy to completely prevent, or reverse neuropathy associated with IGR and this represents a considerable challenge in rehabilitation. There is a particularly strong incentive to prevent IGT and related complications from advancing to DM2. IGR is a growing problem among all older adults and its strong association with many functional limitations, particularly mobility limitations, is not always recognized, even though diabetes-related disability occurs in up to 2/3 of older adults with diabetes and is associated with dependency, poor quality of life, and increased acute and long-term care utilization. Autonomic dysfunction is a significant problem in subjects with IGT. The Preliminary Data shows that over 90% of subjects with IGT have an abnormal score on questionnaires about autonomic symptoms such as lightheadedness, dry mouth or dry eyes, pale or blue feet, feet that are colder than the rest of the body, decreased sweating in the feet or increased sweating in the hands, nausea or bloating after eating, persistent diarrhea or constipation, or leaking of urine. In addition, patients with IGR have impaired balance control. These factors can increase the risk of falls in affected subjects. A non-randomized and non-controlled study showed that a diet and exercise intervention in patients with diabetes led to an overall improvement in autonomic function. Furthermore, it was shown that standing balance can be improved with a balance intervention program. However, there are no published studies that assess the effect of an intense physical activity intervention on autonomic function in IGR related neuropathy. This study will test an aerobic exercise and

Interventions

  • BEHAVIORAL lifestyle modification

Study Locations (1)

Maryland

  • Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD - Baltimore

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2013-11-14
Est. Completion 2026-11-30
Phase NA

Sponsor

VA Office of Research and Development

1,668 total trials

What the Registry Record Tells You About NCT01864460

The ClinicalTrials.gov registry entry for NCT01864460 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (98% lower). The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Diabetes appearing as the primary indexed condition, and to 1 intervention - of which lifestyle modification is the first listed.

NCT01864460 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT01864460 about?

NCT01864460 is a clinical study titled "Improving Autonomic Function and Balance in Diabetic Neuropathy". Type 2 diabetes (DM2) affects nearly 20 million people in the United States while impaired glucose regulation (IGR), which includes impaired glucose tolerance (IGT), impaired fasting glucose (IFG), and early diabetes affects a considerably larger but unknown population group. At the current time the...

What is the current status of trial NCT01864460?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2013-11-14. Estimated completion is 2026-11-30.

What conditions does trial NCT01864460 study?

This clinical trial studies the following conditions: Diabetes, Neuropathy, Impaired Glucose Tolerance.

What interventions are being tested in trial NCT01864460?

The interventions under investigation include: lifestyle modification (BEHAVIORAL).

Who is sponsoring clinical trial NCT01864460?

This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01864460 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.